Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy
The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma. Of 50 patients evaluable for response, 4% achieved complete response (CR), 64% partial response (PR), 18% minimal response (M...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[December 15, 2001]
|
| In: |
Blood
Year: 2001, Jahrgang: 98, Heft: 13, Pages: 3846-3848 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.V98.13.3846 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.V98.13.3846
|
| Verfasserangaben: | Thomas M. Moehler, Kai Neben, Axel Benner, Gerlinde Egerer, Fatime Krasniqi, Anthony D. Ho, and Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1794145176 | ||
| 003 | DE-627 | ||
| 005 | 20230427031004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220301s2001 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.V98.13.3846 |2 doi | |
| 035 | |a (DE-627)1794145176 | ||
| 035 | |a (DE-599)KXP1794145176 | ||
| 035 | |a (OCoLC)1341445482 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Möhler, Thomas |e VerfasserIn |0 (DE-588)1014877261 |0 (DE-627)705298051 |0 (DE-576)34979572X |4 aut | |
| 245 | 1 | 0 | |a Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy |c Thomas M. Moehler, Kai Neben, Axel Benner, Gerlinde Egerer, Fatime Krasniqi, Anthony D. Ho, and Hartmut Goldschmidt |
| 264 | 1 | |c [December 15, 2001] | |
| 300 | |b Diagramme | ||
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.03.2022 | ||
| 520 | |a The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma. Of 50 patients evaluable for response, 4% achieved complete response (CR), 64% partial response (PR), 18% minimal response (MR), 6% stable disease (SD), and 8% progressive disease (PD), resulting in an objective response rate (≥ MR) of 86.0% (76.7% overall objective response rate in intent-to-treat analysis; n = 56). Subsequent to successful remission induction, 18 patients received autologous or allogeneic stem cell transplantation. The median progression-free survival in all patients was 16 months. The median overall survival time could not be calculated, since the last observed death occurred after 16 months of follow-up (median follow-up of 14 months) with a corresponding estimated survival probability of 55%. Severe adverse effects (World Health Organization III/IV) included infectious complications (35.7%) and cardiovascular events (7.1%). The data suggest that Thal improves antitumor activity of salvage chemotherapy regimens in poor-prognosis multiple myeloma. | ||
| 700 | 1 | |a Neben, Kai |d 1969- |e VerfasserIn |0 (DE-588)120842181 |0 (DE-627)080920470 |0 (DE-576)292411774 |4 aut | |
| 700 | 1 | |a Benner, Axel |d 1959- |e VerfasserIn |0 (DE-588)106584686X |0 (DE-627)81687221X |0 (DE-576)425536602 |4 aut | |
| 700 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 700 | 1 | |a Krasniqi, Fatime |e VerfasserIn |0 (DE-588)131350005 |0 (DE-627)50796408X |0 (DE-576)298422662 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 98(2001), 13 vom: Dez., Seite 3846-3848 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy |
| 773 | 1 | 8 | |g volume:98 |g year:2001 |g number:13 |g month:12 |g pages:3846-3848 |g extent:3 |a Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood.V98.13.3846 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220301 | ||
| 993 | |a Article | ||
| 994 | |a 2001 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 7 |y j | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 131350005 |a Krasniqi, Fatime |m 131350005:Krasniqi, Fatime |d 910000 |d 910100 |e 910000PK131350005 |e 910100PK131350005 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |e 910000PE105502168X |e 910100PE105502168X |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 120842181 |a Neben, Kai |m 120842181:Neben, Kai |d 910000 |d 910100 |e 910000PN120842181 |e 910100PN120842181 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1014877261 |a Möhler, Thomas |m 1014877261:Möhler, Thomas |d 910000 |d 910100 |e 910000PM1014877261 |e 910100PM1014877261 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1794145176 |e 407635494X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy","title_sort":"Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy"}],"language":["eng"],"person":[{"display":"Möhler, Thomas","given":"Thomas","family":"Möhler","role":"aut"},{"family":"Neben","display":"Neben, Kai","given":"Kai","role":"aut"},{"role":"aut","display":"Benner, Axel","given":"Axel","family":"Benner"},{"display":"Egerer, Gerlinde","given":"Gerlinde","family":"Egerer","role":"aut"},{"display":"Krasniqi, Fatime","given":"Fatime","family":"Krasniqi","role":"aut"},{"display":"Ho, Anthony Dick","given":"Anthony Dick","family":"Ho","role":"aut"},{"role":"aut","family":"Goldschmidt","display":"Goldschmidt, Hartmut","given":"Hartmut"}],"name":{"displayForm":["Thomas M. Moehler, Kai Neben, Axel Benner, Gerlinde Egerer, Fatime Krasniqi, Anthony D. Ho, and Hartmut Goldschmidt"]},"origin":[{"dateIssuedKey":"2001","dateIssuedDisp":"[December 15, 2001]"}],"recId":"1794145176","note":["Gesehen am 01.03.2022"],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1468538-3"],"issn":["1528-0020"],"eki":["266886647"]},"part":{"issue":"13","extent":"3","volume":"98","text":"98(2001), 13 vom: Dez., Seite 3846-3848","pages":"3846-3848","year":"2001"},"note":["Gesehen am 21.04.2023"],"origin":[{"dateIssuedKey":"1946","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","publisher":"American Society of Hematology ; Saunders ; HighWire Press","dateIssuedDisp":"1946-"}],"corporate":[{"display":"American Society of Hematology","role":"isb"}],"title":[{"title":"Blood","subtitle":"journal of the American Society of Hematology","title_sort":"Blood"}],"pubHistory":["1.1946 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"266886647","disp":"Salvage therapy for multiple myeloma with thalidomide and CED chemotherapyBlood","language":["eng"],"titleAlt":[{"title":"Blood online"}]}],"physDesc":[{"noteIll":"Diagramme","extent":"3 S."}],"id":{"eki":["1794145176"],"doi":["10.1182/blood.V98.13.3846"]},"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a MOEHLERTHOSALVAGETHE1520 | ||